Related Experiment Video
Updated: Jul 22, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice
C J Lees1, V Apostolopoulos, B Acres
1The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia.
Vaccine
|August 10, 2000
Abstract:
Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8(+) cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.
